ArcherDX (RCHR) has filed a preliminary prospectus for a $100M IPO.
The Boulder, CO-based biotech has developed five
research-use-only (RUO) diagnostic product lines that laboratories use
to conduct genomic analyses for cancer therapy optimization and
monitoring. It plans to file marketing applications for STRATAFIDE, a
multigene pan-solid tumor companion diagnostic, and its Personalized
Cancer Monitoring (PCM) assay with the FDA aimed at marketing both as in
vitro diagnostic tests.
2019 Financials: Revenue: $50.6M (+78%); Operating Expenses: $87.8M (+163%); Net Loss: ($41.0M) (-632%); Cash Flow Ops: ($37.5M) (-715%).
https://seekingalpha.com/news/3580952-archerdx-on-deck-for-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.